Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.
Giuseppe Procopio
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Pfizer
Elena Verzoni
No relevant relationships to disclose
Roberto Iacovelli
No relevant relationships to disclose
Isabella Testa
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose
Nicola Nicolai
No relevant relationships to disclose
Luca Porcu
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose